News
A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...
Tocilizumab significantly reduced 28-day mortality and length of ICU stay in patients with severe COVID-19 pneumonia and low S-spike nAb titers.
Research highlights media misrepresentation of COVID-19 drug efficacy. ... For the study, the researchers conducted an analysis of 479 reports of hydroxychloroquine, ...
The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.
FDA recognizes uncertainty in COVID-19 booster efficacy; ... commends new U.S. Food and Drug ... of RT-PCR-confirmed symptomatic COVID-19. The latest analysis from the Phase 3 ...
Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously ...
Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.
To further improve the drug-like features of WYS-633, also with an eye towards oral bioavailability, the team performed another round of medical chemistry, AI-enabled computational analysis, and in ...
AstraZeneca said its latest figure on the vaccine’s efficacy was based on an analysis of 190 cases of symptomatic Covid-19 in the trial, 49 more cases than the company had analyzed earlier ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results